Improved survival with vemurafenib in melanoma with BRAF V600E mutation
- PMID: 21639808
- PMCID: PMC3549296
- DOI: 10.1056/NEJMoa1103782
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Abstract
Background: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.
Methods: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths.
Results: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.
Conclusions: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Figures
Comment in
-
Been there, not done that--melanoma in the age of molecular therapy.N Engl J Med. 2011 Jun 30;364(26):2547-8. doi: 10.1056/NEJMe1105792. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639809 No abstract available.
-
Vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med. 2011 Oct 13;365(15):1448; author reply 1450. doi: 10.1056/NEJMc1108651. N Engl J Med. 2011. PMID: 21995398 No abstract available.
-
Vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med. 2011 Oct 13;365(15):1448-9; author reply 1450. doi: 10.1056/NEJMc1108651. N Engl J Med. 2011. PMID: 21995399 No abstract available.
-
Vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med. 2011 Oct 13;365(15):1449-50; author reply 1450. doi: 10.1056/NEJMc1108651. N Engl J Med. 2011. PMID: 21995400 No abstract available.
Similar articles
-
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.Ann Oncol. 2017 Oct 1;28(10):2581-2587. doi: 10.1093/annonc/mdx339. Ann Oncol. 2017. PMID: 28961848 Free PMC article. Clinical Trial.
-
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27. Lancet Oncol. 2014. PMID: 24582505 Clinical Trial.
-
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.Lancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7. Lancet Oncol. 2014. PMID: 24508103 Free PMC article. Clinical Trial.
-
Vemurafenib: in unresectable or metastatic melanoma.BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000. BioDrugs. 2012. PMID: 22946753 Review.
-
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Clin Ther. 2012. PMID: 22742884 Review.
Cited by
-
Management of Localized Melanoma in the Anti-PD-1 Era.Curr Oncol Rep. 2024 Jun 6. doi: 10.1007/s11912-024-01556-z. Online ahead of print. Curr Oncol Rep. 2024. PMID: 38842606 Review.
-
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.NPJ Precis Oncol. 2024 May 31;8(1):124. doi: 10.1038/s41698-024-00615-9. NPJ Precis Oncol. 2024. PMID: 38822082 Free PMC article.
-
Targeting RAF dimers in RAS mutant tumors: From biology to clinic.Acta Pharm Sin B. 2024 May;14(5):1895-1923. doi: 10.1016/j.apsb.2024.02.018. Epub 2024 Feb 28. Acta Pharm Sin B. 2024. PMID: 38799634 Free PMC article. Review.
-
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors.Cell Mol Life Sci. 2024 May 25;81(1):238. doi: 10.1007/s00018-024-05280-6. Cell Mol Life Sci. 2024. PMID: 38795180 Free PMC article.
-
SEOM-GEM clinical guidelines for cutaneous melanoma (2023).Clin Transl Oncol. 2024 May 15. doi: 10.1007/s12094-024-03497-2. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38748192
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300. 2010. Erratum, CA Cancer J Clin 2011;61:133-4. - PubMed
-
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase no. 10 Lyon, France: International Agency for Research on Cancer. 2010 http://globocan.iarc.fr.
-
- Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–51. - PubMed
-
- Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–66. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials